BCG Unresponsive Disease

(14:50)

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies

(3:4)

4.17.2020 Urology COViD Didactics - BCG Unresponsive Bladder Cancer

(58:31)

Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC

(49)

Investigating novel treatment options for BCG-unresponsive urothelial carcinoma

(1:18)

Management of BCG Unresponsive Cystectomy Ineligible Bladder Cancer Patients Pembrolizumab

(10:35)

Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer

(1:55)

Practical Approaches to BCG Unresponsive Bladder Cancer

(3:18)

Emerging Treatments for BCG Unresponsive Non-muscle Invasive Bladder Cancer

(11:45)

BCG-Unresponsive Bladder Cancer: Rechallenging With Rescue BCG

(5:10)

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

(19:31)

BCG Unresponsive Disease: A Roadmap for Drug Development and Novel Therapies

(20:53)

BCG Unresponsive Non-Muscle Invasive Bladder Cancer

(21:4)

KEYNOTE-057 Cohort B: pembrolizumab for BCG-unresponsive, high-risk NMIBC

(2:1econd)

Introduction to Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC

(29:46)

Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS #bladdercancer #cancer #news

(27)

Scott Tagawa, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive NMIBC

(1:12)

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

(3:17)

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

(2:2)